Irbesartan Mylan (Irbesartan)

Irbesartan selectively blocks angiotensin II type 1 (AT1) receptors, preventing angiotensin II from causing vasoconstriction and stimulating aldosterone release. This leads to relaxed blood vessels, reduced peripheral resistance, and lower blood pressure, while also decreasing stress on the kidneys.

The appropriate dose of Irbesartan Mylan is determined by the prescribing clinician based on the patient’s medical condition, response to therapy, and any concomitant medications. Dosage adjustments are made individually and should follow the prescriber’s instructions.

The safety of Irbesartan during pregnancy has not been established, and it is generally avoided because it may affect fetal development. Limited data exist for breastfeeding; therefore, the drug should only be used if the potential benefit outweighs the risk, under medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Irbesartan belongs to the angiotensin II receptor blocker (ARB) class, offering blood‑pressure control similar to ACE inhibitors but with a lower incidence of cough. Compared with other ARBs, its efficacy and safety profile are comparable, though individual response may vary.

Irbesartan Mylan should be stored at temperatures below 25 °C, in the original container, protected from moisture and direct sunlight. Maintaining these conditions helps preserve the tablet’s stability and potency throughout its shelf life.

Irbesartan Mylan is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider.

Serious risks include angioedema (swelling of the face, lips, tongue, or throat), severe hyperkalaemia, acute kidney injury, and marked hypotension. Patients should seek immediate medical attention if they experience swelling, difficulty breathing, sudden weakness, or a rapid decline in kidney function.

Irbesartan is contraindicated in patients with known hypersensitivity to the drug or any ARB component. It should also be avoided in pregnant women and in individuals with severe hepatic impairment unless specifically directed by a physician.